金黄色葡萄球菌
表皮葡萄球菌
抗菌剂
微生物学
细菌素
抗菌肽
体内
生物
化学
细菌
遗传学
生物技术
作者
Benjamin O. Torres Salazar,Taulant Dema,Nadine A. Schilling,Daniela Janek,Jan Bornikoel,Anne Berscheid,Ahmed M. A. Elsherbini,Sophia Krauss,Simon Jaag,Michael Lämmerhofer,Min Li,Norah Alqahtani,Malcolm J. Horsburgh,Tilmann Weber,José M. Beltrán‐Beleña,Heike Brötz‐Oesterhelt,Stephanie Grond,Bernhard Krismer,Andreas Peschel
出处
期刊:Nature microbiology
日期:2023-12-18
卷期号:9 (1): 200-213
被引量:3
标识
DOI:10.1038/s41564-023-01544-2
摘要
Antagonistic bacterial interactions often rely on antimicrobial bacteriocins, which attack only a narrow range of target bacteria. However, antimicrobials with broader activity may be advantageous. Here we identify an antimicrobial called epifadin, which is produced by nasal Staphylococcus epidermidis IVK83. It has an unprecedented architecture consisting of a non-ribosomally synthesized peptide, a polyketide component and a terminal modified amino acid moiety. Epifadin combines a wide antimicrobial target spectrum with a short life span of only a few hours. It is highly unstable under in vivo-like conditions, potentially as a means to limit collateral damage of bacterial mutualists. However, Staphylococcus aureus is eliminated by epifadin-producing S. epidermidis during co-cultivation in vitro and in vivo, indicating that epifadin-producing commensals could help prevent nasal S. aureus carriage. These insights into a microbiome-derived, previously unknown antimicrobial compound class suggest that limiting the half-life of an antimicrobial may help to balance its beneficial and detrimental activities.
科研通智能强力驱动
Strongly Powered by AbleSci AI